Project Grant W81XWH1910612

This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and evaluation of an innovative approach to target mesothelioma, a devastating form of cancer. The $696,447 award will enable researchers at the University of Virginia to build on their discovery of a novel tumor-selective antibody that binds to the CD46 epitope, which is highly expressed across all major mesothelioma subtypes. The research aims to...

This Project Grant award from the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395) provides $1,408,844 to the Sloan-Kettering Institute for Cancer Research to characterize the diagnostic and therapeutic potential of DLL3-targeting agents for treating high-grade neuroendocrine carcinomas of the lung and prostate. The key objectives are to evaluate a DLL3-targeted radiolabeled monoclonal antibody (89Zr-DFO-SC16.56) for PET imaging of DLL3 expression in tumor...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,020,645 in funding to Rush University Medical Center to conduct research on targeting synthetic lethal vulnerabilities in non-small cell lung cancers (NSCLCs) harboring co-mutations in KRAS and KEAP1. The key products and services being delivered under this grant include: Establishing that the histone deacetylase (HDAC4/5) inhibitor LMK235 specifically targets KRAS/KEAP1 co-mutant...

The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,999,108 Project Grant to Orbit Genomics, Inc. to develop a high-sensitivity, high-specificity lung cancer subtyping diagnostic test. The goal is to create a test that can accurately differentiate between small cell lung carcinoma (SCLC), non-small cell lung carcinoma (NSCLC), and NSCLC subtypes (squamous cell carcinoma, adenocarcinoma, large cell carcinoma). This...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $2,078,214 to Precision Epigenomics Inc., a University of Arizona spin-out company, to conduct a multi-site clinical validation study for their Sentinel-MPE liquid biopsy assay. The Sentinel-MPE test is designed to improve the diagnosis of malignant pleural effusions, which are a significant challenge in clinical practice. The aims of this project are to establish the...

This $1,139,931 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the Medical University of South Carolina and the University of Texas Health Science Center at San Antonio aimed at targeting the SET oncoprotein to induce necroptosis and suppress non-small cell lung cancer (NSCLC). The researchers will define the mechanisms by which the drug FTY720 induces necroptosis in NSCLC cells through the formation of ceramidosomes,...

This federal Project Grant award of $1,313,806.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The key focus is on developing and translating chimeric antigen receptor (CAR) T-cell therapies targeting the cancer-associated antigen mesothelin for the treatment of solid tumors, particularly malignant pleural mesothelioma. The research aims to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $194,013.00 to the University of Southern California to develop a new monoclonal antibody therapy targeting isoaspartylated ELAVL4 protein for the treatment of small cell lung cancer (SCLC). The key objectives are to: 1) Generate a mouse monoclonal antibody specifically binding to the isoaspartylated form of the ELAVL4 protein, which is expressed on the surface of SCLC tumors...

This $215,985 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports a pilot study to develop early biomarkers for predicting patient response to combined immune checkpoint inhibitor therapy for metastatic renal cell carcinoma (RCC). The researchers at Stanford University will sequence exosomal RNA from blood and urine samples collected at baseline, 3 weeks, and 6 weeks after initiating treatment with...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...